A2 share price frenzy – but is the US formula market worth it?

A2 share price frenzy – but is the US formula market worth it?
The American dream may not be worth it for A2. (Image: Getty)
Jenny Ruth
Some investors believe accessing the US infant formula market would be a big deal for Fonterra and the A2 Milk Company, and trading in A2’s shares last week highlighted that fact.An Australian Financial Review (AFR) journalist got a little over her skis on Tuesday and published a story saying A2 could get US Food & Drug Administration (FDA) approval “as soon as this week”.Both Fonterra and A2 have been waiting for this approval since they applied in late May after the FDA made public it was looking to facilitate infant for...

More Primary Sector

Jarden: reassuring to see a more 'bullish' horticulture outlook
Finance

Jarden: reassuring to see a more 'bullish' horticulture outlook

Scales has had a tough year but there are signs of new growth. 

Fonterra fattens margins when its farmers are getting squeezed
Finance

Fonterra fattens margins when its farmers are getting squeezed

The co-op released its quarter one results on Thursday.

Riley Kennedy 08 Dec 2023
Fonterra lifts payout, earning forecast
Finance

Fonterra lifts payout, earning forecast

The lift comes after the recent lift in global prices.

Riley Kennedy 07 Dec 2023